Dr. Fauci encouraged hospitals and physicians to make greater use of the therapy during the briefing.
“We want people out there, including physicians as well as potential patients, to realize the advantage of this very effective way of treating early infection,” Dr. Fauci said. “Clinical trials have demonstrated that early treatment with anti-SARS-CoV-2 monoclonal antibodies can reduce the risk of COVID-19 hospitalization or death by 70 [percent] to 85 percent.”
People who are obese, pregnant, have chronic conditions or are age 65 or older may benefit from the therapy, Dr. Fauci said. Regeneron’s antibody cocktail is also authorized for use in preventing infection in people exposed to the virus, he added.
“Bottom line is this is a very effective intervention for COVID-19,” Dr. Fauci said. “It is underutilized and we recommend strongly that we utilize this to its fullest.”
At present, three monoclonal antibody products are authorized for emergency use by the FDA.
To view the full treatment guidelines for monoclonal antibodies, click here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
